Immunomedics Extends Patent Life on Therapeutic Antibodies NASDAQ MORRIS PLAINS, N.J., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc.(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune ... |
